Sponsor Dossier
Evaris Pharma
Sponsor Dossier for Evaris Pharma. ARTG portfolio, PBS-listed brands, PBAC activity, AusPAR record — compiled by arcimedes.
- Brand: BURN
- Brand: CALCIUM
- Brand: Chlorhexidine
- Brand: DeBug
- Brand: HYDROGEN
- Brand: HYGI-PREP
- Brand: LIDOCAINE
- Brand: MUCOSOOTHE
- Device (sponsor): Applicator, vaginal, single use
- Device (sponsor): Cavity-wound management dressing
- Device (sponsor): Skin semi-occlusive dressing
- Device (sponsor): Skin semi-occlusive dressing
- Device (sponsor): General-body orifice lubricant, sterile
- Device (sponsor): General-body orifice lubricant, sterile
- Device (sponsor): Organ preservation solution
- Device (sponsor): Lubricant, <specify>
About
Evaris Pharma is an Australian Private Company with ABN 56009293136, registered in Western Australia and currently active. The company operates under the business name Evaris Pharma, which has been in effect since November 2024.
Portfolio
Evaris Pharma has 15 brands on the ARTG, of which 2 are indexable and 2 carry a Product Information document. 1 brand is PBS-listed, 1 has a PBAC outcome on record, and 1 has an AusPAR on record. Notable brands include BURN, CALCIUM, Chlorhexidine, DeBug, HYDROGEN, HYGI-PREP, LIDOCAINE, MUCOSOOTHE, OBSTETRIC CARE, ORION, ORIPRO, PERRIGO.
Therapeutic focus
— Infectious Disease: 6 brands — Reproductive Health: 3 brands — Pain Management: 3 brands — Dermatology: 2 brands — Psychiatry: 1 brand
PBS footprint
1 brand is PBS-listed, with the latest PBS schedule date 2026-11-01.
Regulatory activity
The latest PBAC outcome is 2021-11-01, across 1 brand with a PBAC outcome on record. The latest AusPAR is 2020-02-13, across 1 brand with an AusPAR on record.